1. Recchia, F., de Filippis, S., Torchio, P., Rea, S., Gulino, A., Quaglino, D., and Frati, L., Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study, Am. J. Clin. Oncol., 1997, vol. 20, no. 2, pp. 209–214.
2. Sylvester, R.K., Clinical applications of colony-stimulating factors: a historical perspective, Am. J. Health Syst. Pharm., 2002, vol. 59, pp. 6–12.
3. Waller, E.K., The role of sargramostim (rhGM-CSF) as immunotherapy, Oncologist, 2007, vol. 12, pp. 22–26.
4. Polovinkina, V.S. and Kosorukov, V.S., Recombinant rhGM-CSF in oncology, Ross. Bioterapevt. Zh., 2009, vol. 8, no. 1, pp. 29–39.
5. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines, J. Clin. Oncol., 1994, vol. 12, no. 11, pp. 2471–2508.